There's never a shortage of losers in the stock market.
Let's take a closer look at five of this past week's biggest sinkers.
|Aug. 3||Weekly Loss||My Watchlist|
|Halozyme Therapeutics (Nasdaq: HALO )||$4.61||(53%)||Add|
|Zipcar (Nasdaq: ZIP )||$6.75||(39%)||Add|
|Molycorp (NYSE: MCP )||$11.49||(34%)||Add|
|Dendreon (Nasdaq: DNDN )||$4.45||(29%)||Add|
|RealD (NYSE: RLD )||$9.87||(23%)||Add|
Halozyme Therapeutics was clobbered after the FDA rejected its drugs.
Zipcar went in reverse after the car-sharing service posted brutal quarterly results that missed Wall Street's top- and bottom-line targets. The leading provider of auto rentals by the hour also presented soft guidance for the current quarter.
Molycorp took a hit after stunning the market with a steep and unexpected quarterly loss. Sluggish prices for the company's rare-earth minerals are holding Molycorp back.
Cancer-drug developer Dendreon tumbled after posting a wide loss and announcing a cost-cutting plan that includes closing down one of its manufacturing facilities.
RealD screened a horror movie after posting a quarterly profit that clocked in at just a third of what analysts were expecting. Increasing costs and an unflattering mix of recycled 3-D eyewear in shipments slammed margins.
Ready for a bounce
It was a rough week for these five stocks. If you want to shake yesterday's losers and ride tomorrow's winners, a new special report reveals Motley Fool's top stock for 2012. It's free, but only for a limited time, so check it out now.